Margaux explained that the Centers for Medicare and Medicaid will be under inquiry when it selects the inaugural 10 drugs for Medicare’s price negotiations. The 10 drugs will belong to a pool of products with relatively high total costs to Medicare Part D, but the selection process isn't straightforward.
Andrew noted that health care and life sciences companies that contract with or receive grants from the federal government may be subject to scrutiny under the U.S. Department of Justice Civil Cyber-Fraud Initiative. He also said that Medicare Advantage has been on DOJ's short list of False Claims Act priorities.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.